About this trial
Postoperative ileus (POI) is a common complication after abdominal surgery, causing symptoms like nausea, vomiting, abdominal distension, and delayed passage of flatus and stool. Management remains challenging, with limited pharmacological options available. Prucalopride, a selective serotonin 5-HT4 receptor agonist, has shown promise in accelerating gastrointestinal recovery after surgery. However, the optimal timing and dosing for preventing POI remains unclear. Higher doses may provide more potent prokinetic effects in the postoperative setting. his study investigates if higher doses of prucalopride (4 mg) improve bowel function return and hospital stay in elective colorectal surgery patients compared to standard doses and placebo.
Eligibility criteria
Qualifiers
undergoing elective colorectal surgery, including but not limited to colectomy, rectal resection, and sigmoid resection.
Disqualifiers
Emergency surgery
Total colectomy
Creation of a stoma
Pre-existing gastrointestinal disorders
Trial design
Treatments tested in this trial
- Prucalopride 2mg
- Prucalopride 4mg
- Standard Care